Cytokinetics, Incorporated (NASDAQ:CYTK) has been assigned an average recommendation of “Buy” from the fourteen research firms that are currently covering the stock, Marketbeat Ratings reports. Two analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $21.33.

Several equities research analysts recently weighed in on CYTK shares. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price target on shares of Cytokinetics, in a report on Tuesday, April 25th. Zacks Investment Research downgraded Cytokinetics, from a “hold” rating to a “strong sell” rating in a report on Thursday, May 4th. Cowen and Company reaffirmed an “outperform” rating and set a $19.00 price target (up from $17.00) on shares of Cytokinetics, in a report on Saturday, April 29th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Cytokinetics, in a report on Friday, May 19th. Finally, ValuEngine raised Cytokinetics, from a “sell” rating to a “hold” rating in a report on Friday, June 2nd.

ILLEGAL ACTIVITY WARNING: This news story was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and reposted in violation of United States & international trademark & copyright law. The original version of this news story can be accessed at https://www.thecerbatgem.com/2017/08/09/analysts-set-cytokinetics-incorporated-cytk-price-target-at-21-71-updated-updated-updated.html.

Cytokinetics, (CYTK) opened at 12.50 on Tuesday. Cytokinetics, has a 52-week low of $8.51 and a 52-week high of $17.20. The firm has a 50 day moving average of $13.67 and a 200-day moving average of $12.97. The stock’s market cap is $602.71 million.

Cytokinetics, (NASDAQ:CYTK) last posted its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.57) by $0.03. The firm had revenue of $3.05 million during the quarter, compared to analyst estimates of $5.28 million. Cytokinetics, had a negative net margin of 16.00% and a negative return on equity of 14.15%. Equities analysts anticipate that Cytokinetics, will post ($2.08) earnings per share for the current fiscal year.

In other news, CEO Robert I. Blum sold 5,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $13.62, for a total value of $68,100.00. Following the completion of the transaction, the chief executive officer now owns 94,785 shares in the company, valued at $1,290,971.70. The sale was disclosed in a document filed with the SEC, which is available at this link. In the last 90 days, insiders sold 15,000 shares of company stock valued at $197,750. Company insiders own 7.20% of the company’s stock.

Hedge funds have recently bought and sold shares of the company. Nine Chapters Capital Management LLC bought a new stake in Cytokinetics, during the first quarter worth approximately $265,000. Parametric Portfolio Associates LLC boosted its stake in Cytokinetics, by 1.4% in the first quarter. Parametric Portfolio Associates LLC now owns 13,333 shares of the biopharmaceutical company’s stock worth $171,000 after buying an additional 189 shares in the last quarter. TFS Capital LLC bought a new stake in Cytokinetics, during the first quarter worth approximately $1,233,000. Capital Fund Management S.A. bought a new stake in Cytokinetics, during the first quarter worth approximately $213,000. Finally, Wells Fargo & Company MN boosted its stake in Cytokinetics, by 46.9% in the first quarter. Wells Fargo & Company MN now owns 39,308 shares of the biopharmaceutical company’s stock worth $505,000 after buying an additional 12,542 shares in the last quarter. Hedge funds and other institutional investors own 59.76% of the company’s stock.

Cytokinetics, Company Profile

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions.

Analyst Recommendations for Cytokinetics, (NASDAQ:CYTK)

Receive News & Stock Ratings for Cytokinetics Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytokinetics Incorporated and related stocks with our FREE daily email newsletter.